Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Phase 2 Withdrawn Centre Hospitalier Universitaire de Besancon

RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates efficacy, safety and quality of life in patients affected by metastatic breast cancer RH+/ HER2- and treated by estramustine phosphate.

Timeline

Start: 2017-01
Primary completion: 2020-01
Completion: 2020-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	estramustine	Other / unclassified	560 mg	Oral

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Summary

Timeline

Drugs

Indications